Self.co raises 2.56 million euros

The Lithuanian digital health start-up Self.co has closed a financing round totaling 2.56 million euros. EUR 1.2 million of this comes from a venture round led by Iron Wolf Capital, in which Coinvest, NGL Ventures and several business angels also participated. Self.co received a further 1.36 million euros in funding from the Innovation Agency Lithuania.

The company intends to use the fresh capital to further develop its entry-level allergy and intolerance tests and expand into new markets. These include Germany, Austria, Ireland and the United Kingdom. The aim is to make precise diagnoses significantly cheaper and more accessible.

Billion-dollar market with a diagnostic gap

According to the European Academy of Allergy and Clinical Immunology (EAACI), around 40 percent of the world's population is affected by allergies, but almost half remain misdiagnosed or undiagnosed. Long waiting times, limited specialist capacity and high testing costs make access difficult.

In public healthcare systems, patients often have to wait more than six months for an appointment. Conventional molecular tests cost between 200 and 400 euros. As a result, millions continue to live with symptoms such as fatigue, skin irritation or digestive problems without knowing what they are actually suffering from.

High-tech diagnostics at a fraction of the cost

Self.co wants to change that. The company is developing molecular allergy tests that can be carried out at home or in partner clinics using a simple blood sample. In the laboratory, 98 allergens and 220 food intolerances are analyzed with the same precision as clinical tests.

Thanks to in-house production and digitalized processes, Self.co can reduce costs by up to 75 percent. A test costs between 69 and 99 euros. The food intolerance test is currently available on the website for €159.00 and the allergy test for €139.00 (as of 11.11.2025) The results are evaluated using an AI-supported analysis process that combines medical data with clinical expertise. Users then receive a personalized diet and treatment plan tailored to their allergens and symptoms.

Millions of people live with allergy-like symptoms without a clear answer. We have developed a system that combines medical accuracy and digital simplicity. It allows everyone to find out what is really behind their symptoms at a fair price.

autvydas Gylys, co-founder and CEO of Self.co

Investors back digital health platform

For the investors, Self.co is an example of applied biotechnology with great market potential.

Self.co addresses a massive, previously underserved health problem. We are convinced by the combination of technical depth, medical understanding and clear market orientation. The team has the potential to change allergy diagnostics worldwide.

Kasparas Jurgelionis, Managing Partner at Iron Wolf Capital

Expansion into a platform for allergy management

Self.co intends to use the new capital not only to improve its tests, but also to build a holistic digital health platform, from initial diagnosis to treatment and long-term support. Interactive symptom questionnaires, deeper integration with existing healthcare systems and new collaborations with doctors and pharmacies are planned.

Have self-tests been around for a long time in Germany?

Self.co wants to become the leading digital platform for allergy and intolerance management in Europe by 2030. At first glance, Self.co's business model seems familiar to me. NanoRepro AG from Marburg, which also offers self-tests to be sent in, comes to mind. The company became particularly well known during the pandemic when the existing delivery channels were used for the first COVID tests. This had the effect that the share price exploded from €0.58 to €16.00 within a month. Today, people are familiar with the products from retail outlets or their posters on highway service stations.

Self.co also requires a self-taken blood sample, similar to NanoRepro tests for coeliac disease or iron deficiency. NanoRepro mainly offers its products for €11.95 per test, while Self.co charges €159.00 for the analysis of 220 food intolerances. It remains to be seen whether such self-sampled blood tests will be accepted by the market in the long term, especially as comparable diagnoses are available free of charge from doctors in Germany as part of basic medical care.